Eruptions in Patients with chronic hepatitis C receiving combination therapy with Telaprevir, Peginterferon and Ribavirin

被引：0
|
作者：
Eleftheriadis, V [1 ]
Stadler, R. [1 ]
机构：
[1] Johannes Wesling Klinikum Minden, Hautklin, Minden, Germany
来源：
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2012年 / 10卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：869 / 869
页数：1
相关论文
共 50 条
  • [1] ITPA GENE VARIANTS AND ANEMIA DURING TELAPREVIR/PEGINTERFERON/RIBAVIRIN COMBINATION THERAPY IN PATIENTS WITH CHRONIC HEPATITIS C INFECTION
    Tuefferd, M.
    Palescandolo, E.
    Vijgen, L.
    Colombo, M.
    Roberts, S.
    Wedemeyer, H.
    Zeuzem, S.
    De Meyer, S.
    Demasi, R.
    Witek, J.
    Lonjon-Domanec, I.
    Aerssens, J.
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S490 - S490
  • [2] Limitation of combination therapy of peginterferon and ribavirin for older patients with chronic hepatitis C
    Iwasaki, Yoshiaki
    Araki, Yasuyuki
    Takaguchi, Kouichi
    Taniguchi, Hideaki
    Okamoto, Ryoichi
    Kawaguchi, Mitsuhiko
    Terada, Ryo
    Osawa, Toshiya
    Fujioka, Shin-Ichi
    Nagano, Takuya
    Kita, Keiji
    Yamamoto, Kazuhide
    Takaki, Akinobu
    Kobashi, Haruhiko
    Sakaguchi, Kohsaku
    Shiratori, Yasushi
    GASTROENTEROLOGY, 2007, 132 (04) : A794 - A795
  • [3] Efficacy in patients with dose reduction in combination therapy of peginterferon and ribavirin for chronic hepatitis c
    Arase, Yasuji
    Suzuki, Fumitaka
    Sezaki, Hitomi
    Kawamura, Yusuke
    Suzuki, Yoshiyuki
    Kobayashi, Masahiro
    Akuta, Norio
    Hosaka, Tetsuya
    Yatsuji, Hiromi
    Hirakawa, Miharu
    Kobayashi, Mariko
    Ikeda, Kenji
    Kumada, Hiromitsu
    INTERVIROLOGY, 2008, 51 (01) : 1 - 6
  • [4] Renal impairment during the treatment of telaprevir with peginterferon and ribavirin in patients with chronic hepatitis C
    Fukuda, Kazuto
    Imai, Yasuharu
    Hiramatsu, Naoki
    Irishio, Keiko
    Igura, Takumi
    Sawai, Yoshiyuki
    Kogita, Sachiyo
    Makino, Yuki
    Mizumoto, Rui
    Matsumoto, Yasushi
    Nakahara, Masanori
    Zushi, Sinichiro
    Kajiwara, Nobuyuki
    Oze, Tsugiko
    Kawata, Sumio
    Hayashi, Norio
    Takehara, Tetsuo
    HEPATOLOGY RESEARCH, 2014, 44 (12) : 1165 - 1171
  • [5] A pilot study of triple therapy with telaprevir, peginterferon and ribavirin for elderly patients with genotype 1 chronic hepatitis C
    Hara, Tasuku
    Akuta, Norio
    Suzuki, Fumitaka
    Sezaki, Hitomi
    Suzuki, Yoshiyuki
    Hosaka, Tetsuya
    Kobayashi, Masahiro
    Kobayashi, Mariko
    Saitoh, Satoshi
    Kumada, Hiromitsu
    JOURNAL OF MEDICAL VIROLOGY, 2013, 85 (10) : 1746 - 1753
  • [6] COST-UTILITY ANALYSIS OF TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALPHA AND RIBAVIRIN IN PREVIOUSLY TREATED PATIENTS WITH CHRONIC HEPATITIS C
    Lukac, M.
    Bielik, J.
    Holoman, J.
    Tomek, D.
    Suvadova, A.
    Foltanova, T.
    Foltan, V
    VALUE IN HEALTH, 2012, 15 (07) : A330 - A330
  • [7] Correlation of serum ribavirin concentration with pretreatment renal function estimates in patients with chronic hepatitis C receiving combination antiviral therapy with peginterferon and ribavirin
    Toyoda, H.
    Kumada, T.
    Kiriyama, S.
    Sone, Y.
    Tanikawa, M.
    Hisanaga, Y.
    Kanamori, A.
    Atsumi, H.
    Nakano, S.
    Arakawa, T.
    Honda, T.
    Hayashi, K.
    Katano, Y.
    JOURNAL OF VIRAL HEPATITIS, 2008, 15 (09) : 651 - 658
  • [8] Predictors of thyroid dysfunction in patients with chronic hepatitis C during peginterferon and ribavirin combination therapy
    Jang, E. S.
    Kim, W.
    Park, D-J
    Kim, B-H
    Jung, Y-J
    Kim, D-H
    Kim, Y. J.
    Yoon, J-H
    Lee, H-S
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2008, 23 : A40 - A40
  • [9] Reply to: Renal impairment during the treatment of telaprevir with peginterferon and ribavirin in patients with chronic hepatitis C
    Sakin, Yusuf Serdar
    Polat, Zulfikar
    Demirci, Hakan
    Kekilli, Murat
    Uygun, Ahmet
    Bagci, Sait
    HEPATOLOGY RESEARCH, 2014, 44 (09) : 1037 - 1037
  • [10] Telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in chronic hepatitis C patients
    Zeuzem, Stefan
    JOURNAL OF HEPATOLOGY, 2008, 49 (02) : 157 - 159
12345